BYETTA (5 µg to gange dagligt i 4 uger, efterfulgt af 10 µg to gange dagligt) resulterede i en statistisk signifikant reduktion af HbA1c fra baseline, sammenlignet med placebo (- 0, 8% mod +0, 1%) samt signifikant reduktion af legemesvægt (- 1, 5 mod - 0, 2 kg).
BYETTA (5 µg BID for 4 weeks, followed by 10 µg BID) resulted in statistically significant reductions from baseline HbA1c compared to placebo (-0.8% versus +0.1%) as well as significant reductions in body weight (-1.5 versus -0.2 kg).